Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;39(1):9-20.
doi: 10.1007/s12149-024-01998-2. Epub 2024 Nov 5.

Research trends and hotspots of radioiodine-refractory thyroid cancer treatment in the twenty-first century: a bibliometric analysis

Affiliations

Research trends and hotspots of radioiodine-refractory thyroid cancer treatment in the twenty-first century: a bibliometric analysis

Yuhang Xue et al. Ann Nucl Med. 2025 Jan.

Abstract

The treatment of radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) has made significant advancements in the twenty-first century. This study aimed to assess the current state of research and identify potential new directions by conducting a bibliometric analysis of scientific publications on RAIR-DTC treatment. Publications relevant to RAIR-DTC, published from January 1, 2000, to December 31, 2023, were retrieved from the Web of Science Core Collection. Bibliometric analyses of major keywords, authors, countries, institutions, publications, and journals were conducted using CiteSpace and VOSviewer. A total of 859 papers were included in the analysis. The results demonstrated a rising trend in the number of publications over time. The United States was identified as the leading contributor in terms of publication output, citations, and international collaborations. Gustave Roussy emerged as the top organization in publication productivity, while the journal Thyroid had the highest number of related publications. The research on RAIR treatment was categorized into three key hotspots: clinical trials of targeted therapies, novel therapeutic strategies, and debates surrounding the RAIR-DTC management. RAIR-DTC research is expanding from the clinical trial phase of tyrosine kinase inhibitor monotherapy to a more complex combination therapy strategy, in particular, the synergistic effect of immune checkpoint inhibitors and other therapeutic agents, requiring more high-quality prospective studies to validate the clinical benefits. Moreover, the timely identification of RAIR-DTC patients holds the potential to enable early disease intervention, constituting a pivotal novel research direction in the future.

Keywords: Bibliometric analysis; Citespace; Radioiodine-refractory; Thyroid cancer; Treatment; VOSviewer.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare that they have no potential conflict of interest.

Figures

Fig. 1
Fig. 1
Flowchart illustrating the literature screening process
Fig. 2
Fig. 2
The number of articles published in the twenty-first century and the trend in the growth of the annual number of articles
Fig. 3
Fig. 3
a World map depicting the number of publications by country. Circle size represents the volume of publications, while the thickness of the connecting lines indicates the strength of collaboration between countries. b The percentage of total publications contributed by the eight countries with the highest number of articles in the field
Fig. 4
Fig. 4
Analysis of the top 15 authors and 10 institutions by publication volume. a The top 15 authors' number of papers, total citations, average number of citations, intensity of collaboration, and average time to publication. b Institutional affiliation and country of the top 15 authors with the most publications. c Number of documents and average citations for the 10 most published institutions
Fig. 5
Fig. 5
a Number of publications and average citations for the top 10 journals with the highest article counts. b Dual-overlay graph of journals in the field of RAIR-DTC treatment
Fig. 6
Fig. 6
Chronological timeline of pivotal articles in RAIR-DTC treatment research
Fig. 7
Fig. 7
a Co-occurrence mapping of key terms, displaying 60 keywords with a minimum occurrence threshold of 5. b Distribution of keywords based on their average year of publication

Similar articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. - PubMed
    1. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317:1338. - PMC - PubMed
    1. Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–90. - PMC - PubMed
    1. Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer. 2016;23:R185-205. - PubMed
    1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources